Zura Bio
Innovating treatments for severe immune system conditions.
Launch date
Employees
Market cap
€215m
Enterprise valuation
€215m (Public information from Sep 2024)
Share price
$4.3 ZURA
San Diego California (HQ)
Financials
Estimates*
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 4.2m |
| EBITDA | (<1m) | (27.2m) | (64.8m) | - | - | - |
| Profit | 6.8m | (25.7m) | (60.4m) | (34.9m) | (55.7m) | (79.7m) |
| % profit margin | - | - | - | - | - | (1913 %) |
| EV / revenue | - | - | - | - | - | 62.6x |
| EV / EBITDA | - | - | -3.1x | - | - | - |
| R&D budget | - | 23.7m | 44.0m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $120m Valuation: $215m -242.0x EV/LTM EBITDA | SPAC IPO | |
* | N/A | $65.0m | SPAC Private Placement |
* | $80.0m | Post IPO Equity | |
* | $113m | Private Placement VC | |
| Total Funding | €161m | ||